302 related articles for article (PubMed ID: 34061852)
21. Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States.
Murayama A; Marshall DC
Gynecol Oncol; 2024 Feb; 181():83-90. PubMed ID: 38147713
[TBL] [Abstract][Full Text] [Related]
22. Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States.
Inoue K; Figueroa JF; DeJong C; Tsugawa Y; Orav EJ; Shen C; Kazi DS
Circ Cardiovasc Qual Outcomes; 2021 May; 14(5):e007521. PubMed ID: 33966446
[TBL] [Abstract][Full Text] [Related]
23. Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing.
Qian J; Hansen RA; Surry D; Howard J; Kiptanui Z; Harris I
Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):819-826. PubMed ID: 28485111
[TBL] [Abstract][Full Text] [Related]
24. Influence of pharmaceutical marketing on Medicare prescriptions in the District of Columbia.
Wood SF; Podrasky J; McMonagle MA; Raveendran J; Bysshe T; Hogenmiller A; Fugh-Berman A
PLoS One; 2017; 12(10):e0186060. PubMed ID: 29069085
[TBL] [Abstract][Full Text] [Related]
25. Provider-directed marketing may increase prescribing of medications for opioid use disorder.
Nguyen T; Andraka-Christou B; Simon K; Bradford WD
J Subst Abuse Treat; 2019 Sep; 104():104-115. PubMed ID: 31370974
[TBL] [Abstract][Full Text] [Related]
26. Physician Payments from Pharmaceutical Companies Related to Cancer Drugs.
Mitchell AP; Mishra Meza A; Trivedi NU; Bach PB; Gönen M
Oncologist; 2022 Oct; 27(10):857-863. PubMed ID: 35946837
[TBL] [Abstract][Full Text] [Related]
27. Experts' agency problems: evidence from the prescription drug market in Japan.
Iizuka T
Rand J Econ; 2007; 38(3):844-62. PubMed ID: 18478669
[TBL] [Abstract][Full Text] [Related]
28. Pharmaceutical payments to physicians may increase prescribing for opioids.
Nguyen TD; Bradford WD; Simon KI
Addiction; 2019 Jun; 114(6):1051-1059. PubMed ID: 30667135
[TBL] [Abstract][Full Text] [Related]
29. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies.
Hollenbeck BK; Oerline M; Kaufman SR; Caram MEV; Dusetzina SB; Ryan AM; Shahinian VB
Urology; 2021 Feb; 148():134-140. PubMed ID: 33075381
[TBL] [Abstract][Full Text] [Related]
30. The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications.
Modi PK; Wang Y; Kirk PS; Dupree JM; Singer EA; Chang SL
Urology; 2018 Jul; 117():50-56. PubMed ID: 29680480
[TBL] [Abstract][Full Text] [Related]
31. Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs.
Perlis RH; Perlis CS
PLoS One; 2016; 11(5):e0155474. PubMed ID: 27183221
[TBL] [Abstract][Full Text] [Related]
32. Physician and Patient Adjustment to Reference Pricing for Drugs.
Robinson JC; Whaley C; Brown TT; Dhruva SS
JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
[TBL] [Abstract][Full Text] [Related]
33. Pharmaceutical Industry Payments and Oncologists' Selection of Targeted Cancer Therapies in Medicare Beneficiaries.
Mitchell AP; Winn AN; Dusetzina SB
JAMA Intern Med; 2018 Jun; 178(6):854-856. PubMed ID: 29630687
[TBL] [Abstract][Full Text] [Related]
34. Nonresearch Industry Payments to Radiologists: Characteristics and Associations With Regional Medical Imaging Utilization.
Kokabi N; Junn JC; Xing M; Hemingway J; Hughes DR; Duszak R
J Am Coll Radiol; 2017 Mar; 14(3):418-425.e2. PubMed ID: 28082155
[TBL] [Abstract][Full Text] [Related]
35. Association between physician characteristics and payments from industry in 2015-2017: observational study.
Inoue K; Blumenthal DM; Elashoff D; Tsugawa Y
BMJ Open; 2019 Sep; 9(9):e031010. PubMed ID: 31542759
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Industry Payments to Physicians and Advanced Practice Clinicians.
Zhang AD; Anderson TS
JAMA; 2022 Dec; 328(24):2452-2455. PubMed ID: 36315190
[TBL] [Abstract][Full Text] [Related]
37. Industry Payment to Vascular Neurologists: A 6-Year Analysis of the Open Payments Program From 2013 Through 2018.
Nalleballe K; Sheng S; Li C; Mahashabde R; Annapureddy AR; Mudassar K; Pothineni K; Veerapaneni P; Harada Y; Chilkulwar A; Ranabothu S; Brown A; Kapoor N; Onteddu S
Stroke; 2020 Apr; 51(4):1339-1343. PubMed ID: 32078482
[TBL] [Abstract][Full Text] [Related]
38. Increasing Industry Involvement in Otolaryngology: Insights from 3 Years of the Open Payments Database.
Morse E; Fujiwara RJT; Mehra S
Otolaryngol Head Neck Surg; 2018 Sep; 159(3):501-507. PubMed ID: 29807484
[TBL] [Abstract][Full Text] [Related]
39. Impact of Industry Payments on Prescribing Patterns for Tumor Necrosis Factor Inhibitors Among Medicare Beneficiaries.
Singh P; Forman H; Adamson AS; Mostaghimi A; Ogdie AR; Oganisian A; Barbieri JS
J Gen Intern Med; 2019 Feb; 34(2):176-178. PubMed ID: 30324292
[No Abstract] [Full Text] [Related]
40. Physician characteristics, industry transfers, and pharmaceutical prescribing: Empirical evidence from medicare and the physician payment sunshine act.
Brunt CS
Health Serv Res; 2019 Jun; 54(3):636-649. PubMed ID: 30273976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
